These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7898080)

  • 1. Myocardial salvage efficacy of the thromboxane receptor antagonist ifetroban in ferrets and dogs.
    Gomoll AW; Grover GJ; Ogletree ML
    J Cardiovasc Pharmacol; 1994 Dec; 24(6):960-8. PubMed ID: 7898080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-related cardioprotection by ifetroban in relation to inhibition of thrombosis and ex vivo platelet function.
    Gomoll AW; Schumacher WA; Ogletree ML
    Pharmacology; 1995 Feb; 50(2):92-110. PubMed ID: 7716179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of aspirin to interfere with the cardioprotective effects of ifetroban.
    Gomoll AW; Ogletree ML
    Eur J Pharmacol; 1994 Dec; 271(2-3):471-9. PubMed ID: 7705447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboxane receptor antagonist BMS-180291, but not aspirin, reduces the severity of pacing-induced ischemia in dogs.
    Grover GJ; Schumacher WA; Ogletree ML
    J Cardiovasc Pharmacol; 1994 Sep; 24(3):493-9. PubMed ID: 7528306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion.
    Grover GJ; Schumacher WA; Simon M; Parham C
    J Cardiovasc Pharmacol; 1988 Dec; 12(6):701-9. PubMed ID: 2467089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial salvage efficacy of a thromboxane receptor antagonist, SQ, 30,741, in relation to inhibition ex vivo of platelet function in the ferret.
    Gomoll AW; Ogletree ML
    Prostaglandins; 1993 Sep; 46(3):233-42. PubMed ID: 8234831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the thromboxane receptor antagonist SQ 29,548 on myocardial infarct size in dogs.
    Grover GJ; Schumacher WA
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):29-35. PubMed ID: 2450253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective actions of a thromboxane receptor antagonist, SQ 29548 on the ischemic myocardium: morphologic and hemodynamic effects.
    Singh J; Seth SD; Manchanda SC; Seth S
    Prostaglandins Leukot Essent Fatty Acids; 1997 Feb; 56(2):105-10. PubMed ID: 9051718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of thromboxane A2 in reperfusion injury.
    Grover GJ; Sleph PG; Parham C
    Proc Soc Exp Biol Med; 1988 Sep; 188(4):504-8. PubMed ID: 2971219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia/reperfusion injury in the dog heart.
    Preckel B; Schlack W; Gonzàlez M; Obal D; Barthel H; Thämer V
    Basic Res Cardiol; 2000 Oct; 95(5):404-12. PubMed ID: 11099168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.
    Rosenfeld L; Grover GJ; Stier CT
    Cardiovasc Drug Rev; 2001; 19(2):97-115. PubMed ID: 11484065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of a novel thromboxane antagonist, BAY-U3405, on canine myocardial damage after coronary artery occlusion and reperfusion.
    Fiedler VB; Perzborn E; Seuter F
    Pharmacotherapy; 1991; 11(1):77-84. PubMed ID: 2020615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a thromboxane synthetase inhibitor, Y-20811, on infarct size, neutrophil accumulation, and arrhythmias after coronary artery occlusion and reperfusion in dogs.
    Sato N; Endo T; Kiuchi K; Hayakawa H
    J Cardiovasc Pharmacol; 1993 Mar; 21(3):353-61. PubMed ID: 7681494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of diltiazem on extent of ultimate myocardial injury resulting from temporary coronary artery occlusion in dogs.
    Bush LR; Romson JL; Ash JL; Lucchesi BR
    J Cardiovasc Pharmacol; 1982; 4(2):285-96. PubMed ID: 6175813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function.
    Auchampach JA; Pieper GM; Cavero I; Gross GJ
    Basic Res Cardiol; 1998 Oct; 93(5):361-71. PubMed ID: 9833148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional differences in postischemic recovery in the stunned canine myocardium.
    Farber NE; Pieper GM; Gross GJ
    Am Heart J; 1987 Nov; 114(5):1086-95. PubMed ID: 3673875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in myocardial infarct size by the new potassium channel opener bimakalim.
    Auchampach JA; Gross GJ
    J Cardiovasc Pharmacol; 1994 Apr; 23(4):554-61. PubMed ID: 7516004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 99mTc-tetrofosmin assessment of myocardial perfusion and viability in canine models of coronary occlusion and reperfusion.
    Glover DK; Ruiz M; Koplan BA; Watson DD; Beller GA
    J Nucl Med; 1999 Jan; 40(1):142-9. PubMed ID: 9935070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys.
    Schumacher WA; Steinbacher TE; Youssef S; Ogletree ML
    Prostaglandins; 1992 Nov; 44(5):389-97. PubMed ID: 1301074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.